BEXIMCO PHARMACEUTIC

BXPHARMA
End-of-day quote. End-of-day quote  - 01/19
196.1BDT +1.76%
Valuation
Fiscal Period: June 2021 2022
Capitalization1 79 09687 483
Enterprise Value (EV)1 86 05296 162
P/E ratio 15,4x15,3x
Yield 1,97%1,99%
Capitalization / Revenue 2,68x2,66x
EV / Revenue 2,92x2,93x
EV / EBITDA 11,1x10,9x
Price to Book 2,14x2,13x
Nbr of stocks (in thousands) 446 112446 112
Reference price (BDT) 177196
Announcement Date 11/02/2021-
Previous period Next period
1 BDT in Million
Estimates
Income Statement Evolution
Annual Income Statement Data
Fiscal Period: June 2021 2022
Net sales1 29 49432 835
EBITDA1 7 7658 819
Operating profit (EBIT)1 6 6516 942
Operating Margin 22,5%21,1%
Pre-Tax Profit (EBT)1 6 3786 890
Net income1 5 1415 270
Net margin 17,4%16,0%
EPS2 11,512,8
Dividend per Share2 3,503,90
Announcement Date 11/02/2021-
Previous period Next period
1 BDT in Million
2 BDT
Finances - Leverage
Fiscal Period: June 2021 2022
Net Debt1 6 9568 680
Net Cash position1 --
Leverage (Debt / EBITDA) 0,90x0,98x
Free Cash Flow1 3 4984 940
ROE (Net Profit / Equities) 14,8%14,7%
Shareholders' equity1 34 76435 850
ROA (Net Profit / Asset) 10,0%-
Assets1 51 182-
Book Value Per Share2 83,092,1
Cash Flow per Share --
Capex1 2 5261 990
Capex / Sales 8,56%6,06%
Announcement Date 11/02/2021-
Previous period Next period
1 BDT in Million
2 BDT
Financial Ratios
Size 2022e 2023e
Capitalization 87 483 M BDT -
Enterprise Value (EV) 96 162 M BDT 91 436 M BDT
Valuation 2022e 2023e
P/E ratio (Price / EPS) 15,3x 13,6x
Capitalization / Revenue 2,66x 2,18x
EV / Revenue 2,93x 2,40x
EV / EBITDA 10,9x 9,60x
Yield (DPS / Price) 1,99% 2,19%
Price to book (Price / BVPS) 2,13x 1,91x
Profitability 2022e 2023e
Operating Margin (EBIT / Sales) 21,1% 20,3%
Operating Leverage (Delta EBIT / Delta Sales) 0,39x 0,77x
Net Margin (Net Profit / Revenue) 16,0% 15,1%
ROA (Net Profit / Asset) - -
ROE (Net Profit / Equities) 14,7% 14,8%
Rate of Dividend 30,4% 29,9%
Balance Sheet Analysis 2022e 2023e
CAPEX / Sales   6,06% 4,22%
Cash Flow / Sales - -
Capital Intensity (Assets / Sales) - -
Financial Leverage (Net Debt / EBITDA) 0,98x 0,39x
Price Earning Ratio
Year-on-year evolution of the Yield
Change in Enterprise Value/EBITDA
EPS & Dividend